The purpose of this study is to determine whether a new investigational combination of drugs, that contains belantamab mafodotin with belantamab, will be as effective, and more tolerable, compared to belantamab mafodotin alone in participants with multiple myeloma that has become active again after at least three prior lines of treatment.

By doing this study, we hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to persons with multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy.

The purpose of this study is to find out if an investigational treatment called P-BCMA-ALLO1 is safe and will help treat people with Multiple Myeloma. The study is also being done to determine what dose is safe and effective to treat Multiple Myeloma.

In this study, we want to see what happens when one of the drugs in a 4-drug combination called Dara-RVd is given once a week instead of twice a week. We will look at how this timing change affects the outcome of multiple myeloma with autologous stem cell transplantation. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

We know multiple myeloma can take a long time to diagnose. In this study, we want to better understand how your myeloma was diagnosed so we can identify ways to improve the process.

Have you been diagnosed with cancer. If so, you may be able to take part in a research study looking to improve cancer care for patients whose treatment outcomes have led to challenges in their quality of life.

Have you been diagnosed with Multiple Myeloma? Have you received idecabtagene vicleucel (ide-cel (Abecma)) CAR-T treatment? If so, you may be able to take part in a research study looking at for how long a new drug called iberdomide will keep Multiple Myeloma under control (in remission).

Have you been diagnosed with Smoldering Multiple Myeloma (SMM)? Are you 40 years old or older? If so, you may be able to participate in a study to see if AL-related genes can increase the chances of SMM patients developing AL Amyloidosis in the future.

Are you dealing with multiple myeloma that keeps coming back or hasn't improved? If you are, you may be able to join a study to see if a new drug called ABBV-383 could be safe and helpful for people in your situation. You will be reimbursed for travel expenses. You will not have to pay for the drug while you take part in this study.

Are you interested in improving your physical health and wellbeing during or after cancer treatment? If so, our free 12- week exercise program might be a good fit for you! We are creating a registry of adults with a cancer diagnosis who have gone through our program.